RAs
Page 1: Introduction to Rheumatoid Arthritis (RA)
Learning Objectives
Differentiate RA from osteoarthritis (OA): prevalence, classification, clinical presentation.
Understand guidelines for RA management.
Explore pharmacological treatments for RA.
Determine appropriate therapies (both pharmacologic and non-pharmacologic).
Identify monitoring parameters and preventive measures for RA.
Apply clinical decision-making to practical scenarios.
Introduction to RA
RA is an autoimmune and inflammatory disease requiring early evaluation, diagnosis, and management.
Arthritis-Related Statistics
Prevalence: 54.5 million US adults (~22.7%) have some form of arthritis.
OA (most common) affects over 30 million US adults; costly, with a $16.5 billion annual hospital cost (4.3% of all costs in 2013).
RA impacts approximately 1.3 million US adults; annual cost per patient ~$13,012 versus $4950 for controls; total costs of RA can reach $39.2 billion.
Leading cause of disability with projections of 78 million US adults having arthritis by 2045.
Burden of RA
Onset typically occurs at middle age; women affected 2-3 times more than men.
Disability: 50% of RA patients unable to work within 10 years (historically 50%, current data 35%).
Increased cardiovascular risk: RA patients have a 5x higher CV risk than the general population.
Etiology of RA
Uncertain causes: genes, viruses, environmental factors, and obesity may play roles.
Genetic factors include:
HLA shared epitope for immune response control.
Polymorphisms such as STAT4, TRAF1, and PTPN22 related to chronic inflammation.
Environmental triggers: cigarette smoke, pesticides, infections, obesity.
Page 2: Risk Factors and Symptoms of RA
Risk Factors for RA
Genetics
Female gender
Advancing age (around 50)
Environmental influences
Cigarette smoking (predictor for poor outcomes)
Vitamin D deficiency.
Symptoms of RA and Disease Manifestations
Symptoms
Morning stiffness
Joint swelling and pain
Fatigue and weakness
Fever
Loss of appetite
Disease Manifestations
Cartilage damage
Bone erosion and deformity
Disability and premature death.
Page 3: Laboratory Findings in RA
RA Laboratory Investigations
Test Normal Range Measures Diagnosis/Prognosis | |||
ESR | <20 mm/hr | Indirect acute phase response | Disease activity |
CRP | 0-2 mg/dl | Acute phase response | Disease activity |
RF | <1:16 | Autoantibody for IgG antibodies | Diagnostic tool |
Anti-CCP | Negative | Autoantibody for citrullinated peptides | Specific for RA |
Page 4: Clinical Presentation of RA vs OA
Clinical Presentation Comparison: RA vs OA
Characteristics Rheumatoid Arthritis (RA) Osteoarthritis (OA) | ||
Description | Autoimmune with joint inflammation | Degenerative cartilage breakdown |
Primary Affected Joints | Smaller joints, symmetric | Distal interphalangeal joints |
Joint Characteristics | Soft, warm, tender; bilateral, symmetrical | Hard and bony; unilateral, asymmetrical |
Stiffness | Worse after resting and in the morning | Worse after effort, in the evening |
Laboratory Findings | (+) RF, (+) Anti-CCP, elevated ESR & CRP | (-) RF, (-) Anti-CCP; normal ESR & CRP |
Physical Findings | Local and systemic involvement | Localized joint effects (±Heberden's nodes) |
RA Flares
Symptoms may come and go, lasting days to months.
High disease activity periods may lead to systemic organ impacts.
Classification Criteria
2010 ACR/EULAR Criteria: aids early RA diagnosis.
1987 ACR Criteria: distinguishes established RA.
Page 5: 2010 ACR Classification Criteria for RA
Classification Algorithm
Score ≥6/10 confirms RA, considering joints affected and serological markers (anti-CCP and RF levels).
Assessing Disease Activity
Clinical tools:
RAPID-3
CDAI
DAS28
SDAI
Clinical examination for functionality, pain levels, tender and swollen joints.
Adverse prognostic signs: functional limitations, (+) RF, (+) ACPA, radiographic bony erosions.
ACR Disease Activity Calculators
Instrument Disease Activity Threshold | |
PAS / PAS-II | Remission: 0-0.25; Low: >0.25-3.7; Moderate: <3.71-<8.0; High: >8.0 |
RAPID-3 | Near remission: 1-3; Low: 4-6; Moderate: 7-12; High: 13-30 |
CDAI | Remission: <2.8; Low: 2.8-10.0; Moderate: 10-22.0; High: >22.0 |
DAS | Remission: <2.6; Low: 2.6-3.2; Moderate: 3.2-5.1; High: >5.1 |
SDAI | Remission: <3.3; Low: >3.3-11.0; Moderate: >11-26.0; High: >26.0 |
Page 6: Remission Definition and Treatment Goals
2011 ACR/EULAR Definition of Remission
Boolean-based criteria:
TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dl, PGA ≤ 1 (out of 10 scale).
Various index-based definitions available (RAPID-3, CDAI, DAS, SDAI).
Treatment Goals for RA
Target remission or low disease activity.
Early active intervention is vital (monitoring every 3 months).
Focus on:
Symptom relief
Improving functional outcomes
Reducing long-term complications.
Non-Pharmacological Measures
Rest, physical therapy/exercise (flexibility and conditioning).
Nutritional/dietary counseling, weight control, and tobacco cessation.
Page 7: Pharmacologic Treatment Options for RA
Pharmacologic Treatment Approaches
DMARDs: to slow disease activity/progression.
csDMARDs, bDMARDs (TNFi and non-TNFi), tsDMARDs.
Symptomatic treatment: NSAIDs (non-selective and COX-2 inhibitors), low-dose systemic steroids.
Considerations for RA Pharmacologic Treatment
Assess disease activity, consider past treatments, and patient preferences.
Monitor labs: CBC, SCr, LFTs, and screening for infectious diseases.
2021 ACR Guidelines
Treatment Initiation
Follow the ACR recommendations for initiating treatment.
Page 8: csDMARDs and Their Usage
Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
First-line treatment to prevent progression and joint damage.
Treatment Options
Monotherapy: MTX usually recommended.
Dual therapy: combinations like MTX+SSZ or MTX+HCQ.
Triple therapy: MTX+SSZ+HCQ.
Benefits and Risks of csDMARDs
Pros
Oral administration, widely available, effective, low cost.
Cons
Delayed onset (up to 12 weeks), potential serious side effects, requires monitoring.
Choosing csDMARDs
Specific Drugs
Methotrexate: first-line, effective but need monitoring.
Leflunomide: alternative post-MTX, safer in mild renal impairment.
Hydroxychloroquine: safer option during pregnancy.
Sulfasalazine: used in combination due to better tolerability.
Page 9: Detailed Overview of csDMARDs
csDMARD Medication Overview
Medication Target/MOA Dose Route Adverse Drug Reactions Warnings/Contraindications Monitoring | ||||||
Methotrexate (MTX) | Inhibition of dihydrofolate | 7.5-25 mg weekly | Various routes | N/V/D, ↑LFTs, stomatitis, pregnancy risks | Severe renal/liver impairment | CBC, LFTs |
Leflunomide (LEF) | Inhibits pyrimidine synthesis | 10-20 mg daily | PO | Nausea, headache | Severe hepatic impairment | CBC, BP, LFTs |
Hydroxychloroquine (HCQ) | Impairs antibody reactions | 200-400 mg daily | PO | Nausea, vision changes | Retinopathy risk | Eye exams |
Sulfasalazine (SSZ) | Modulates leukotrienes | 500 mg BID | PO | Nausea, rash, liver toxicity | Sulfa allergy, GI obstruction | CBC, LFTs |
Boxed Warnings for csDMARDs
Specific warnings related to MTX and Leflunomide concerning liver disease and pregnancy.
Page 10: Biologic DMARDs (bDMARDs)
Indications and Benefits of bDMARDs
Used for patients with moderate to severe RA that do not respond to csDMARDs or in combination to enhance efficacy.
Categories
TNF inhibitors vs. Non-TNF inhibitors.
bDMARD Usage
Precautions
Not to use two bDMARDs concurrently due to infection risks.
Guidelines for Treatment
Considerations for dosing and response monitoring.
Page 11: Overview of Non-TNF-α Inhibitors
Non-TNF-α Inhibitor bDMARDs
Medication MOA Route Dose Common ADRs Monitoring | |||||
Abatacept | T-cell co-stimulation | SQ/IV | Appropriate weight-based | URTIs, nausea | Monitor TB |
Rituximab | Anti-B-cell | IV | Two doses 1000 mg 15 days apart | Infusion reactions | Monitor CBC |
Sarilumab | IL-6 receptor antagonism | SQ | 200 mg every 2 weeks | URTIs | Monitor LFTs |
Tocilizumab | IL-6 receptor blocking | SQ/IV | 4-8 mg/kg IV every few weeks | Neutropenia | Monitor LFTs |
Boxed Warnings
Warnings associated with serious infections and malignancy risks for specific drugs.
Page 12: JAK Inhibitors
Targeted Synthetic DMARDs (tsDMARDs)
JAK inhibitors (Tofacitinib, Baricitinib, Upadacitinib).
Interactions and Contraindications
Focused on severe infections and screening requirements.
Monitoring Parameters
Regular laboratory monitoring for lymphocyte counts and liver function.
Page 13: Updates on Monitoring and Tapering Treatment
Updated FDA Warnings
Serious risks associated with JAK inhibitors, such as infection and thrombosis.
Recommendations for Tapering Treatment
Tailor to individual patient needs and monitor closely for flares.
Page 14: Special Populations and Patient Considerations
Management Adjustments
Consider specific populations such as pregnant patients.
Monitor for drug interactions and contraindications with ongoing therapies.
Page 15: Challenges to Medication Adherence
Common Barriers
Financial constraints, lack of healthcare education, miscommunication about treatment goals.
Patient Engagement
Importance of understanding treatment efficacy and management of side effects.
Page 16: Summary of Key Points on RA Management
Key Points
RA is a lifelong condition with no cure that requires early and aggressive treatment.
Importance of a comprehensive treatment plan incorporating both pharmacological and non-pharmacological strategies.
Conclusion and References
Thank you for your attention! Questions welcomed during the session.